Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Jagsonpal Pharmaceuticals's Revenue for the
three
months ended in Jun. 2026 was ₹822 Mil. Jagsonpal Pharmaceuticals's average Accounts Receivable for the
three
months ended in Jun. 2026 was ₹172 Mil.
Hence, Jagsonpal Pharmaceuticals's Receivables Turnover for the
three
months ended in Jun. 2026 was 4.78.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Jagsonpal Pharmaceuticals Receivables Turnover Related Terms
Jagsonpal Pharmaceuticals Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:507789 vs ZTS: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Jagsonpal Pharmaceuticals's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jagsonpal Pharmaceuticals Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jagsonpal Pharmaceuticals's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Jagsonpal Pharmaceuticals's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jagsonpal Pharmaceuticals (BOM:507789) has a Receivables Turnover of 4.78 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Jagsonpal Pharmaceuticals and its competitors. According to the industry distribution chart, Jagsonpal Pharmaceuticals ranks #60 out of 946 companies in the Drug Manufacturers industry, placing it in the top 6.3%.
Is Jagsonpal Pharmaceuticals' Receivables Turnover too high?
Jagsonpal Pharmaceuticals' current Receivables Turnover is 4.78. The Drug Manufacturers industry median Receivables Turnover is 5.09. Jagsonpal Pharmaceuticals' value of 4.78 is 6% below this industry median. Based on the distribution chart, Jagsonpal Pharmaceuticals ranks #60 out of 946 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Jagsonpal Pharmaceuticals has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Jagsonpal Pharmaceuticals' Receivables Turnover compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Jagsonpal Pharmaceuticals ranks #60 out of 946 companies for Receivables Turnover. This places Jagsonpal Pharmaceuticals in the top 6% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.09. Jagsonpal Pharmaceuticals' value of 4.78 is 6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.09, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jagsonpal Pharmaceuticals's current Receivables Turnover of 4.78 is 6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Jagsonpal Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jagsonpal Pharmaceuticals's current Receivables Turnover is 4.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jagsonpal Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jagsonpal Pharmaceuticals (BOM:507789) is currently considered Fairly Valued. The stock's GF Value™ is ₹218.37, compared to a current price of ₹239.75 — trading 9.8% above its estimated fair value. The current Receivables Turnover is 4.78 and 6% below the Drug Manufacturers industry median of 5.09. Jagsonpal Pharmaceuticals' overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Jagsonpal Pharmaceuticals (BOM:507789), the current Receivables Turnover is 4.78 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jagsonpal Pharmaceuticals (BOM:507789) Overvalued in 2026?
Based on GuruFocus' analysis, Jagsonpal Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹239.75 is trading 9.8% above its estimated GF Value™ of ₹218.37.
GuruFocus considers Jagsonpal Pharmaceuticals to be Fairly Valued.
Key valuation signals for BOM:507789:
Receivables Turnover: 4.78
GF Value™: ₹218.37 vs. price of ₹239.75 (9.8% above fair value)
Industry Position: 6% below the Drug Manufacturers median (#60 of 946)
No single metric tells the full story. See the BOM:507789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jagsonpal Pharmaceuticals Ltd is a pharmaceutical company. It develops and manufactures active pharmaceutical ingredients and formulations like Capsule and Tablet. The company operates in the Gynaecology, Orthopaedics, Dermatology and Paediatric segments. Its brands comprise Lycored, Maintane, Doxypal DR, and others.
70GF Score
Get the complete analysis for BOM:507789
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:507789 has been successfully added to your 
